Abstract:Background: Publication of the Women's Health Initiative (WHI) trial results in 2002 significantly reduced physician and patient confidence in and acceptance of hormone replacement therapy (HRT) as an appropriate treatment option for menopause-associated vasomotor symptoms (VMS). This was true despite the fact that the WHI trial was a primary prevention study conducted in postmenopausal women and was not designed to evaluate the efficacy of HRT in the treatment of VMS. Objective: To review data from the WHI, including recent analyses, demonstrating the risks and benefits of HRT in postmenopausal women, to describe changes in menopause treatment guidelines and HRT use since publication of early WHI results nearly 6 years ago, and to identify opportunities for improving the quality of care in perimenopausal women. Summary: Early results from the WHI demonstrated that the risks of longterm HRT in postmenopausal women outweighed the benefits, leading study investigators to conclude that HRT should not be initiated or continued for the primary prevention of coronary heart disease (CHD) in postmenopausal women. Treatment guidelines published by several professional and managed care organizations continue to advocate the use of HRT for treatment of moderate-to-severe VMS. Nevertheless, physician and patient confidence in HRT has declined, as evidenced by a decrease in new HRT prescriptions and an increase in the discontinuation rate of HRT immediately following publication of the preliminary WHI results. Recent analyses demonstrate that the risk for CHD in postmenopausal women is largely dependent upon the age of the woman and the number of years since menopause, with a lower risk for CHD in women aged 50 to 59 years and in women who experienced menopause within the previous 10 years. The highest risk for CHD was evident in women aged 70 to 79 years and in women who experienced menopause 20 or more years ago. Although these data do not support the use of HRT as a primary prevention strategy in postmenopausal women, they do suggest the need to further evaluate the benefits and risks of HRT in perimenopausal women based on patient-specific characteristics, including age and time since menopause. Conclusion: Menopausal women present a unique opportunity for health care providers to improve the quality of care among women, not only as it relates to the treatment of VMS, but also as it relates to osteoporosis and cardiovascular disease, 2 common comorbidities in perimenopausal and postmenopausal women.

Commentary on the Women's Health Initiative

The role of the NIH's Office of Research on Women's Health

Dietary intervention favorably influences physical functioning: the Women's Health Initiative randomized Dietary Modification trial.

Long-term impact of the women’s health initiative on HRT

Menopausal hormone treatment cardiovascular disease: another look at an unresolved conundrum

Coronary Artery Calcification (CAC) and Post‐Trial Cardiovascular Events and Mortality Within the Women's Health Initiative (WHI) Estrogen‐Alone Trial

Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors

Changes in the Use of Postmenopausal Hormone Therapy after the Publication of Clinical Trial Results

Association of calcium and vitamin D supplementation with cancer incidence and cause‐specific mortality in Black women: extended follow‐up of the Women's Health Initiative calcium‐vitamin D trial

The sound and the fury: was it all worth it?

Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies

Evolving issues in the clinical and managed care settings on the management of menopause following the women's health initiative

The 2017 Women's Health Initiative study and use of hormone therapy: an emulated repeated cross-sectional study

Prospective Associations of Waist-to-Height Ratio with Cardiovascular Events in Postmenopausal Women: Results from the Women’s Health Initiative

Perimenopausal and Postmenopausal Health

Estrogen and cardiovascular disease

The Health of Women (HOW) Study®: a web-based survey of breast cancer risk factors, diagnosis, and treatment

Safety and benefit considerations for menopausal hormone therapy

Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials

Metabolomics-Based Biomarker for Dietary Fat and Associations with Chronic Disease Risk in Postmenopausal Women1